Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer
Source : https://jcp.bmj.com/content/early/2021/02/28/jclinpath-2021-207416.abstract
Whenever tissue sample is not available, non-small cell lung cancer (NSCLC) biomarker testing is performed with liquid biopsy. The Kirsten rat sarcoma viral oncogene homolog ( KRAS ) p.G12C mutation...
KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33618059/
KRAS mutation is the most common oncogenic driver in advanced non-small cell lung cancer (NSCLC), occurring in approximately 30% of lung adenocarcinomas. Over 80% of oncogenic KRAS mutations occur at...
Cell-type Specific Adaptive Signaling Responses to KRASG12C inhibition
Source : https://clincancerres.aacrjournals.org/content/early/2021/02/19/1078-0432.CCR-20-3872
Purpose: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. While several combination strategies have...
KRASG12C Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines
Source : https://www.mdpi.com/1422-0067/22/4/2222
KRASG12C is among the most common oncogenic mutations in lung adenocarcinoma and a promising target for treatment by small-molecule inhibitors. KRAS oncogenic signaling is responsible for modulation of tumor microenvironment,...